Therapeutic drug monitoring and virological response at week 48 in a cohort of HIV-1 infected-patients switching to dolutegravir/rilpivirine dual maintenance therapy (ANRS-MIE-BIRIDER Study) - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue British Journal of Clinical Pharmacology Année : 2024

Therapeutic drug monitoring and virological response at week 48 in a cohort of HIV-1 infected-patients switching to dolutegravir/rilpivirine dual maintenance therapy (ANRS-MIE-BIRIDER Study)

Marie-Claude Gagnieu
  • Fonction : Auteur
  • PersonId : 955485
François Parant

Résumé

AIM: Dolutegravir (DTG) and rilpivirine (RPV) dual therapy is now recommended as a switch option in virologically suppressed HIV patients. Literature suggests that virological failure with dual therapy could possibly relate to sub-therapeutic drug concentrations. In this study, we aimed at describing the DTG and RPV trough plasma concentrations (Cmin) and plasma HIV-1 RNA (VL) during maintenance dual therapy. METHODS: We performed a retrospective analysis of DTG and RPV Therapeutic Drug Monitoring in people living with HIV/AIDS (PLWHA) with dual therapy in 9 French centers. DTG and RPV trough plasma concentrations were estimated using a Bayesian approach to predict Cmin. The relationship between the pharmacokinetics of DTG and RPV and VL>50cp/mL was explored using joint non-linear mixed models. The frequency of subtherapeutic threshold (DTG Cmin below 640 ng/mL and RPV Cmin below 50 ng/mL) were compared between PLWHA presenting VL>50 cp/mL or not during the study. RESULTS: At baseline, 209 PLWHA were enrolled in the study. At week 48, 19 people living with HIV/AIDS (9.1%) discontinued their treatment and 15 PLWHA (7.1%) exhibited VL>50 cp/mL. Six PLWHA out of 15 (40.0%) with VL>50 cp/mL during the follow-up had at least one Cmin below the respective thresholds while only 26/194 patients (13.4%) without virological replication had at least one concentration below the threshold (p=0.015). CONCLUSION: A majority of PLWHA receiving DTG/RPV maintenance dual therapy demonstrated VL<50 cp/mL but virological replication was more frequent in people living with HIV/AIDS with subtherapeutic Cmin.
Fichier principal
Vignette du fichier
Lemaitre et al. - 2023 - Therapeutic drug monitoring and virological respon.pdf (1.33 Mo) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-04196341 , version 1 (14-09-2023)

Licence

Paternité - Pas d'utilisation commerciale

Identifiants

Citer

Florian Lemaitre, Jennifer Lagoutte-Renosi, Marie-Claude Gagnieu, François Parant, Nicolas Venisse, et al.. Therapeutic drug monitoring and virological response at week 48 in a cohort of HIV-1 infected-patients switching to dolutegravir/rilpivirine dual maintenance therapy (ANRS-MIE-BIRIDER Study). British Journal of Clinical Pharmacology, 2024, 90 (1), pp.264-273. ⟨10.1111/bcp.15890⟩. ⟨hal-04196341⟩
40 Consultations
3 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More